Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
5.4813
+0.0013 (0.02%)
NASDAQ · Last Trade: Aug 7th, 12:26 PM EDT
Detailed Quote
Previous Close
5.480
Open
5.545
Bid
5.480
Ask
5.490
Day's Range
5.450 - 5.690
52 Week Range
3.790 - 12.36
Volume
7,236,237
Market Cap
923.19M
PE Ratio (TTM)
-3.012
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
31,082,460
Chart
About Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development. By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need. Read More
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share.
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This shift moves beyond generic interactions, creating highly tailored and dynamic digital environments that promise to revolutionize user experience across entertainment, e-commerce, and healthcare. The immediate
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from silicon-based microchips, biocomputers harness the remarkable processing power of biological systems—often using living cells, DNA molecules, or even entire organisms as computational platforms.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes amid growing confidence in the company’s platform, which combines advanced machine learning with high-throughput biological experimentation, signaling a potential paradigm shift in the
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and development. Headquartered in Salt Lake City, Utah, the company has positioned itself at the forefront of the intersection between biotechnology and cutting-edge
